Private equity funds that acquire or manage healthcare providers face direct exposure under the civil False Claims Act, not only the portfolio companies they control. Federal prosecutors and qui tam relators increasingly name the fund, its management company, and individual deal partners alongside the operating entity once a billing scheme surfaces after closing. Under 31 U.S.C. 3729(a)(1)(A), liability reaches anyone who knowingly causes a false claim to be presented, a standard that reaches an investor who never submitted a claim directly and can sweep in board control and a management services agreement, not just the provider that billed Medicare or Medicaid.
How Investors Get Named In An FCA Case
The statute's liability provisions are broader than the claim itself. Section 3729(a)(1)(A) reaches anyone who knowingly presents, or causes to be presented, a false claim for payment. Section 3729(a)(1)(G), the reverse false claims provision, separately reaches a party who knowingly conceals or improperly avoids an obligation to pay money owed to the government. Neither requires the defendant to be the entity that filled out the claim form.
For a private equity owner, causation can turn on control: where the fund's designees hold a majority of a portfolio company's board seats and participate in its oversight, a federal court has allowed False Claims Act liability to proceed on evidence that the fund had the power to fix known regulatory violations that caused false claims but did not act. A passive equity stake raises different causation questions than installing executives or directing the company's billing decisions.
The Knowledge Standard That Reaches Post-Acquisition Conduct
The statute's knowledge standard does the rest of the work. Under 31 U.S.C. 3729(b)(1), knowing or knowingly means a person has actual knowledge of the relevant information, acts in deliberate ignorance of its truth or falsity, or acts in reckless disregard of its truth or falsity. The statute requires no proof of specific intent to defraud.
That standard maps onto the transaction timeline. A due diligence report that flags an upcoding pattern, or an integration plan that continues a practice already known to be noncompliant, can support deliberate ignorance or reckless disregard, even where the fund never reviewed a claim. Because this conduct can surface years later, the civil FCA's limitations period, and how far courts will toll it, sets how far back liability can reach, an issue examined in The FCA Statute of Limitations and the Tolling Fight. The exposure turns on what the fund knew once ownership began, not on when it bought the company.
Why Management Companies Share The Exposure
A PE-backed healthcare platform may route billing and coding through a separate management company under a management services agreement, keeping the provider administratively thin. Where that company sets coding policy or controls claims submission, it can itself cause a false claim to be presented under Section 3729(a)(1)(A), independent of the fund's equity position. This concentrates liability in one entity each time a practice at any portfolio company draws scrutiny, and where more than one relator comes forward across a multi-site platform, which suit controls turns on the rule described in The First-to-File Bar in Qui Tam Litigation.
Exclusion And Integrity Agreement Exposure Beyond The FCA
FCA liability is not the only consequence that can reach an investor. Under 42 U.S.C. 1320a-7(b)(15), the HHS Office of Inspector General can impose an OIG exclusion on an owner or controlling individual who knew or should have known of the conduct underlying a sanction, and on an officer or managing employee. Exclusion bars federal program payment for any item, service, or administrative or management function that person performs at a company billing federal healthcare programs, broader than a damages judgment. A settlement's corporate integrity agreement can bind an entity that later acquires control of the settling provider to the agreement's requirements, and many states, including New Jersey, have enacted parallel false claims statutes, examined in The New Jersey False Claims Act for Healthcare Providers.
Health Law Alliance's attorneys have overseen 2,000+ audits and handled 5,000+ matters, with 25+ years of experience.
A private equity firm that learns a portfolio company is submitting false claims and takes no action can face the same False Claims Act exposure as the company itself.
Why Early Legal Counsel Is Critical
It is critical that healthcare providers, and the investors and management companies that control them, promptly retain experienced healthcare defense counsel upon receiving a subpoena, civil investigative demand, or other government inquiry touching a portfolio company. Early legal intervention can protect the provider's and the investor's rights, ensure appropriate responses to government requests, and preserve relevant defenses. Delaying representation can significantly affect the outcome of a matter and expose both the operating company and its owners to unnecessary risk.
How Health Law Alliance Can Help
Health Law Alliance defends healthcare providers, pharmacies, manufacturers, and corporate defendants when a billing practice draws government attention, from the first qui tam complaint through any resulting settlement. Contact Health Law Alliance for a free, confidential consultation through its false claims act defense practice.
